AU2005229331B2 - Diaminopyrimidines as P2X3 and P2X2/3 antagonists - Google Patents

Diaminopyrimidines as P2X3 and P2X2/3 antagonists Download PDF

Info

Publication number
AU2005229331B2
AU2005229331B2 AU2005229331A AU2005229331A AU2005229331B2 AU 2005229331 B2 AU2005229331 B2 AU 2005229331B2 AU 2005229331 A AU2005229331 A AU 2005229331A AU 2005229331 A AU2005229331 A AU 2005229331A AU 2005229331 B2 AU2005229331 B2 AU 2005229331B2
Authority
AU
Australia
Prior art keywords
isopropyl
methoxy
phenoxy
pyrimidine
diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005229331A
Other languages
English (en)
Other versions
AU2005229331A1 (en
Inventor
Chris Allen Broka
David Scott Carter
Michael Patrick Dillon
Ronald Charles Hawley
Alam Jahangir
Clara Jeou Jen Lin
Daniel Warren Parish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2005229331A1 publication Critical patent/AU2005229331A1/en
Application granted granted Critical
Publication of AU2005229331B2 publication Critical patent/AU2005229331B2/en
Priority to AU2012200211A priority Critical patent/AU2012200211B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005229331A 2004-03-05 2005-02-25 Diaminopyrimidines as P2X3 and P2X2/3 antagonists Expired AU2005229331B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012200211A AU2012200211B2 (en) 2004-03-05 2012-01-13 Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55049904P 2004-03-05 2004-03-05
US60/550,499 2004-03-05
PCT/EP2005/002020 WO2005095359A1 (en) 2004-03-05 2005-02-25 Diaminopyrimidines as p2x3 and p2x2/3 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012200211A Division AU2012200211B2 (en) 2004-03-05 2012-01-13 Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Publications (2)

Publication Number Publication Date
AU2005229331A1 AU2005229331A1 (en) 2005-10-13
AU2005229331B2 true AU2005229331B2 (en) 2011-10-13

Family

ID=34961010

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005229331A Expired AU2005229331B2 (en) 2004-03-05 2005-02-25 Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Country Status (30)

Country Link
US (12) US7858632B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (2) EP2343282B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (4) JP4717876B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR100822530B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN1930135B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (1) AR047992A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU2005229331B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE (1) BE2024C508I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (2) BRPI0508461B8 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2557372C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (2) CY1113450T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (1) DK1725540T5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (2) ES2391636T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FI (1) FIC20240007I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FR (1) FR24C1011I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20120901T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (1) HUS2400005I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (2) IL177438A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LU (1) LUC00333I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY145465A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NL (1) NL301261I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (4) NO339497B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (1) NZ549069A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL1725540T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (1) PT1725540E (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RU (1) RU2422441C2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI1725540T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TWI313604B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2005095359A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA200606880B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
US8592419B2 (en) * 2004-10-29 2013-11-26 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
EP1924264B9 (en) 2005-09-01 2014-02-19 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2374750T3 (es) * 2005-09-01 2012-02-21 F. Hoffmann-La Roche Ag Proceso de síntesis de ariloxidiaminopirimidinas.
CN101300235B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
CN101253159B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
EP1770089A1 (en) * 2005-10-03 2007-04-04 Institut Pasteur Pyranodibenzofuran derivatives with antifungal and antibacterial activity
ES2461595T3 (es) 2006-10-04 2014-05-20 F. Hoffmann-La Roche Ag Proceso para la síntesis de derivados de fenoxi-diaminopirimidina
CA2668399C (en) * 2006-11-09 2015-01-27 Li Chen Thiazole and oxazole-substituted arylamides
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
US8101644B2 (en) 2007-03-30 2012-01-24 Shionogi & Co., Ltd. Pyrrolinone derivative and pharmaceutical composition comprising the same
EP2628727A3 (en) * 2007-11-21 2013-12-25 Decode Genetics EHF Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
EP2336109A4 (en) * 2008-09-25 2012-05-02 Shionogi & Co NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME
CA2742866C (en) 2008-11-06 2017-10-24 Musc Foundation For Research Development Lysosomotropic inhibitors of acid ceramidase
JP5250116B2 (ja) 2008-11-24 2013-07-31 ビーエーエスエフ ソシエタス・ヨーロピア 熱潜在性塩基を含む硬化性組成物
CA2748546A1 (en) * 2008-12-30 2010-07-08 Musc Foundation For Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase
CN102395571B (zh) 2009-02-13 2015-12-16 盐野义制药株式会社 三嗪衍生物及含有该三嗪衍生物的药物组合物
US9567318B2 (en) * 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
US9718790B2 (en) 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
JP6124351B2 (ja) * 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
UA118851C2 (uk) * 2013-08-23 2019-03-25 Ефферент Фармасьютікалз Інк. Способи застосування діамінопіримідинових модуляторів р2х3 та р2х2/3 рецепторів для лікування гострого та підгострого кашлю, позиву до кашлю та хронічного кашлю при респіраторних хворобах
ES2774975T3 (es) 2014-05-13 2020-07-23 Memorial Sloan Kettering Cancer Center Moduladores de hsp70 y métodos para fabricar y utilizar el mismo
WO2016004358A1 (en) 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
CA2957804C (en) 2014-09-09 2023-04-04 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
RU2585727C1 (ru) * 2014-12-12 2016-06-10 Наталья Борисовна Гусева Способ лечения детей с гиперактивным мочевым пузырем
PL3355889T3 (pl) 2015-09-29 2023-05-22 Afferent Pharmaceuticals Inc. Modulatory receptorów diaminopirymidynowych p2x3 i p2x2/3 do stosowania w leczeniu kaszlu
CA3016773A1 (en) * 2016-03-14 2017-09-21 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
CN108779119B (zh) 2016-03-25 2022-02-08 传入制药公司 嘧啶及其变体、及其用途
CN106083653A (zh) * 2016-06-06 2016-11-09 江苏天和制药有限公司 奥美普林中间体肉桂腈的合成方法
US10676444B2 (en) * 2016-12-20 2020-06-09 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
AU2018361276B2 (en) * 2017-11-01 2022-11-24 Beijing Tide Pharmaceutical Co., Ltd. P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
AU2019257606B2 (en) * 2018-04-23 2025-01-30 Msd Werthenstein Biopharma Gmbh Novel process for synthesis of a phenoxy diaminopyrimidine compound
EP3807243B1 (en) * 2018-06-15 2024-05-22 Pharmathen S.A. A novel process for the preparation of tapentadol
SG11202111877TA (en) * 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Method for treating cough by using diaminopyrimidine compound
JP7650821B2 (ja) 2019-04-30 2025-03-25 ベイジン タイド ファーマシューティカル カンパニー リミテッド ジアミノピリミジン化合物又はその水和物の固体形態、その調製方法及びその適用
MX2021014115A (es) * 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
CN113924293B (zh) * 2019-06-06 2024-07-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
CN110551147B (zh) * 2019-09-29 2021-11-26 蚌埠产品质量监督检验研究院 一种3-环丙基苯硼酸的合成方法
TWI849314B (zh) 2020-06-01 2024-07-21 日商住友化學股份有限公司 化合物、樹脂、抗蝕劑組成物及抗蝕劑圖案的製造方法
JP2023536986A (ja) 2020-08-13 2023-08-30 上海拓界生物医薬科技有限公司 ベンズイミダゾール誘導体、その調製方法及び医薬用途
EP4214195A1 (en) 2020-09-17 2023-07-26 Teva Pharmaceuticals International GmbH Solid state forms of gefapixant and process for preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657206A (en) * 1951-07-30 1953-10-27 Burroughs Wellcome Co 2, 4-diamino-5-aryloxy-pyrimidines
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2658897A (en) 1951-06-27 1953-11-10 Burroughs Wellcome Co 2, 4-diamino-5-benzyl pyrimidines
US2909522A (en) 1957-02-21 1959-10-20 Burroughs Wellcome Co Trialkoxybenzylpyrimidines and method
US3849470A (en) * 1969-03-06 1974-11-19 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US3991050A (en) * 1969-03-06 1976-11-09 Burroughs Wellcome Co. Preparation of β-Amino-α-benzylacrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
US3852276A (en) * 1969-03-06 1974-12-03 Burroughs Wellcome Co 5-benzyl pyrimidines intermediate therefore, and method
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3855265A (en) * 1969-03-06 1974-12-17 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore, and method
US3850927A (en) * 1969-03-06 1974-11-26 Burroughs Wellcome Co 5-benzyl pyrimidines intermediates therefore,and method
US4052553A (en) * 1969-03-06 1977-10-04 Burroughs Wellcome Co. 5-benzyl pyrimidines intermediates therefore, and method
BR6915082D0 (pt) * 1969-05-16 1973-03-08 Wellcome Found Processo de preparacao de benzil-pirimidinas
CH513181A (de) * 1969-06-12 1971-09-30 Hoffmann La Roche Verfahren zur Herstellung von N-Oxyden von Benzylpyrimidinen
US4255574A (en) * 1973-02-26 1981-03-10 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-pyrimidines
US4143227A (en) * 1973-02-26 1979-03-06 Hoffmann-La Roche Inc. Process for substituted 5-benzyl-2,4-diamino-pyrimidines
US3931181A (en) * 1973-07-27 1976-01-06 Hoffmann-La Roche Inc. 2,4-Diamino-5-benzylpyrimidines
US4515948A (en) * 1973-09-12 1985-05-07 Hoffmann-La Roche Inc. 2,4-Diamino-5-(4-amino and 4-dimethylamino-3,5-dimethoxy benzyl)pyrimidines
CH591457A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) * 1973-11-08 1977-09-15 Hoffmann La Roche
US3940393A (en) * 1974-06-21 1976-02-24 American Home Products Corporation Synthesis of 2,6-diaminopyrimidines
US4039543A (en) * 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
US4033962A (en) * 1975-06-26 1977-07-05 Hoffman-La Roche Inc. 2,4-Diamino-pyrimidine derivatives and processes
GB1582245A (en) * 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
US4115650A (en) * 1976-11-17 1978-09-19 Hoffmann-La Roche Inc. Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines
US4075209A (en) * 1977-02-07 1978-02-21 Hoffmann-La Roche, Inc. Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate
FR2397407A2 (fr) * 1977-07-11 1979-02-09 Dick Pierre Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides
US4258045A (en) * 1979-11-30 1981-03-24 Merck & Co., Inc. Inhibitor of dihydrofolate reductase
DE3045720A1 (de) * 1980-12-04 1982-07-08 Basf Ag, 6700 Ludwigshafen N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2502152A1 (fr) * 1981-03-20 1982-09-24 Panmedica Laboratoires Nouveaux derives solubles n2 substitues de la diamino-2,4-benzyl-5-pyrimidines, leur procede de preparation et medicaments les contenant
IT1138146B (it) * 1981-08-11 1986-09-17 Proter Spa Processo per la produzione della 2,4-diammino-(3,5-dimetossi-4-metos sietossi-benzil)-pirimidina
GB2116962A (en) * 1982-03-18 1983-10-05 Ciba Geigy Ag Nitriles; pyrimidines
US4590271A (en) * 1982-05-01 1986-05-20 Burroughs Wellcome Co. 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4587341A (en) * 1982-05-07 1986-05-06 Burroughs Wellcome Co. 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials
US4515574A (en) * 1983-02-16 1985-05-07 The Zeller Corporation Universal joint seal with multiple lips
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
FR2595697B1 (fr) * 1986-03-13 1988-07-08 Rousselot Cie Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant
HU199683B (en) * 1987-07-22 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions analgesic, antiphlogistic, antipyretic, antianginic and/or antioxidative activity
US4996198A (en) * 1988-07-11 1991-02-26 Hoffmann-La Roche Inc. Anticoccidial composition
US5240640A (en) * 1990-06-04 1993-08-31 Coulter Corporation In situ use of gelatin or an aminodextran in the preparation of uniform ferrite particles
US5258373A (en) * 1991-07-17 1993-11-02 Hoffmann-La Roche Inc. Anticoccidial compositions
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
WO1996016963A1 (de) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6211185B1 (en) * 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
CA2361402C (en) 1999-09-03 2009-05-12 Actelion Pharmaceuticals Ltd Bis-sulfonamides
PL207590B1 (pl) 1999-09-24 2011-01-31 Janssen Pharmaceutica Nv Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US6515198B2 (en) * 2000-02-15 2003-02-04 Syntex (U.S.A.) Llc Use of purinergic receptor modulators and related reagents
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
BR0114082A (pt) 2000-09-25 2003-07-22 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
BRPI0116237B8 (pt) 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
WO2002083650A1 (en) 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
CA2447671C (en) * 2001-05-18 2013-01-08 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
CN101300235B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
CN101253159B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
EP1924264B9 (en) * 2005-09-01 2014-02-19 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657206A (en) * 1951-07-30 1953-10-27 Burroughs Wellcome Co 2, 4-diamino-5-aryloxy-pyrimidines
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CALAS et al: "synthese d'analogues nouveaus de la trimethoprime etude de relation structure-activite antibacterienne" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 17, no. 6, 1982, pages 497-504. *
DIAS SELASSIE, C. et al: " Quantitative structure-activity relationships of 2,4-diamino-5-(2-x-benzyl)pyrimidines versus bacteria1 and avian dihydrofolate reductase" JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pg 4261-72. *
DUNN, S.M.J. et al: "Kinetics of ternary complex formation between dihydrofolate reductase, coenzyme, and inhibitors" BIOCHEMISTRY, vol. 19, 1980, pages 766- 773. *
FALCO, E.A. et al: "5-Arylthiopyrimidines I: 2,4-diamino derivatives" JOURNAL OF ORGANIC CHEMISTRY, vol. 26, 1961, pages 1143-1146. *
SEILER, P. et al: "Partition coefficients of 5-(substituted benzy1)-2,4-diaminopyrimidines". ARZNEIM. -FORSCH., Vol. 32, no. 7, 1982, pages 711-714. *

Also Published As

Publication number Publication date
HUS2400005I1 (hu) 2024-04-28
IL217453A (en) 2014-12-31
KR100822530B1 (ko) 2008-04-16
NO20161635A1 (no) 2016-10-12
TWI313604B (en) 2009-08-21
CY1113450T1 (el) 2016-06-22
US20180141919A1 (en) 2018-05-24
US20250066309A1 (en) 2025-02-27
US9556127B2 (en) 2017-01-31
EP2343282A1 (en) 2011-07-13
NL301261I2 (nl) 2024-03-25
BR122018003623B8 (pt) 2021-07-27
US20190016688A1 (en) 2019-01-17
WO2005095359A1 (en) 2005-10-13
AR047992A1 (es) 2006-03-15
FR24C1011I2 (fr) 2024-12-13
BRPI0508461A (pt) 2007-07-31
EP1725540A1 (en) 2006-11-29
US20140357629A1 (en) 2014-12-04
HK1101074A1 (en) 2007-10-05
CY2024006I2 (el) 2024-09-20
IL177438A0 (en) 2006-12-10
FIC20240007I1 (fi) 2024-03-13
NO339497B1 (no) 2016-12-19
US20240158356A1 (en) 2024-05-16
MY145465A (en) 2012-02-15
JP2007526268A (ja) 2007-09-13
HRP20120901T1 (hr) 2012-12-31
JP2011126899A (ja) 2011-06-30
CN1930135A (zh) 2007-03-14
IL217453A0 (en) 2012-02-29
JP5886898B2 (ja) 2016-03-16
SI1725540T1 (sl) 2012-12-31
FR24C1011I1 (fr) 2024-05-24
US7858632B2 (en) 2010-12-28
DK1725540T5 (da) 2012-10-22
CA2557372A1 (en) 2005-10-13
US8846705B2 (en) 2014-09-30
US20230100975A1 (en) 2023-03-30
US20210009531A1 (en) 2021-01-14
CA2557372C (en) 2013-01-08
NO20150504L (no) 2006-11-28
ZA200606880B (en) 2008-04-30
US20050209260A1 (en) 2005-09-22
JP2011252004A (ja) 2011-12-15
BRPI0508461B1 (pt) 2018-05-15
US20110077242A1 (en) 2011-03-31
PL1725540T3 (pl) 2013-02-28
US20190270713A1 (en) 2019-09-05
BRPI0508461B8 (pt) 2021-05-25
AU2005229331A1 (en) 2005-10-13
JP4717876B2 (ja) 2011-07-06
ES2548022T3 (es) 2015-10-13
BE2024C508I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2024-08-08
RU2422441C2 (ru) 2011-06-27
JP5576314B2 (ja) 2014-08-20
EP2343282B1 (en) 2015-07-22
CY2024006I1 (el) 2024-09-20
ES2391636T3 (es) 2012-11-28
CN1930135B (zh) 2011-12-28
NO2024010I1 (no) 2024-03-06
US20170096404A1 (en) 2017-04-06
TW200539885A (en) 2005-12-16
PT1725540E (pt) 2012-11-29
RU2006135203A (ru) 2008-04-10
DK1725540T3 (da) 2012-10-01
EP1725540B1 (en) 2012-09-12
US20200115347A1 (en) 2020-04-16
BR122018003623B1 (pt) 2018-10-09
NO20064065L (no) 2006-11-28
JP5465700B2 (ja) 2014-04-09
KR20060117366A (ko) 2006-11-16
IL177438A (en) 2012-10-31
NO343755B1 (no) 2019-05-27
LUC00333I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2024-10-04
JP2014193906A (ja) 2014-10-09
NZ549069A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
AU2005229331B2 (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
AU2006286601B2 (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
AU2012200211B2 (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired